In a quiet lab at UC San Francisco, 10,000 miniature tumors—each no larger than a poppy seed—are growing in stacks of plastic plates, their fates being shaped by a robotic arm that moves with the precision of a master surgeon. These tiny clusters of cancer cells are not just lab curiosities—they’re battlegrounds in the fight against recurrence, where a handful of elusive "persister" cells survive even the most aggressive treatments, only to reignite tumors months or years later. Now, thanks to a groundbreaking robotic platform developed by researchers at UCSF, scientists can finally track these resilient cells at scale, uncovering patterns that may one day break the cycle of relapse for cancer patients.
Persister cells have long been a mystery. They’re rare—sometimes just one in 1,000 tumor cells—and genetically identical to the rest of the tumor, making them nearly invisible to conventional detection. Worse, their survival traits can vanish once removed from their environment, slipping through the fingers of researchers like smoke. But their impact is devastating: they’re believed to be the root cause of cancer’s return, forcing patients into repeated rounds of grueling therapy. To confront this challenge, Xiaoxiao "Vany" Sun, Ph.D., and her team built ResMap, a high-throughput robotic system capable of testing thousands of drug combinations on mini tumors in parallel. The platform automates every step—from dosing with sound-wave precision to staining and imaging—enabling a level of consistency and scale impossible by hand.
The team tested 94 drug candidates, each previously flagged as potentially effective against persister cells, across two types of lung cancer that had already been treated with standard therapies. The result? Nine drugs consistently weakened persister cells, regardless of the initial treatment. This discovery is profound: it suggests that despite their varied origins, persister cells may share common biological vulnerabilities. "We expected each tumor to behave as its own special case," said Steve Altschuler, Ph.D., professor of pharmaceutical chemistry at UCSF and co-senior author of the study. "Instead, we found patterns that held up across many different samples, suggesting there may be underlying rules that can help predict which therapies are most likely to work."
Published in Science Advances, the findings offer more than just a list of promising compounds—they lay the foundation for a systematic approach to targeting residual cancer. The ResMap platform is designed to expand, with plans to include more tumor types and treatment histories. The ultimate goal is to create a public resource that maps persister cell dependencies across contexts, accelerating the development of therapies that prevent relapse before it starts. For patients who’ve endured the emotional and physical toll of recurring cancer, this work offers a quiet but powerful hope: that the next treatment might be the last one they need.